Chairman–Dr Ron Weinberger BSc (Hons), PhD
Ron Weinberger joined 3DMorphic initially to provide strategic advice to an early stage company. After working in academia and then in the biomedical sector, Dr Weinberger joined Nanosonics Ltd (NAN) in August 2004. He was involved in the listing of NAN on the ASX in 2007. Ron was appointed as Executive Director and Board Member, in July 2008 and held that Board role for 8 years. He was appointed as CEO in May 2011 and then Managing Director which position he held for almost three years. As CEO, Ron grew Nanosonics from a market capitalisation of approximately $100M to approximately $240M within 2 years in a challenging economic environment. He grew annual revenue from $2.3M revenue to $14.9M over the same period and positioned NAN for near-term profitability. Today NAN has a market cap. of about $800M. Ron has held multiple roles at NAN from heading R&D/Regulatory, strategically building the IP portfolio and establishing USA operations. In commercialising the NAN product portfolio he developed distribution agreements with multinational companies such as Toshiba in the UK and Miele Professional in Germany and was a signatory on the USA GE Healthcare distribution agreement. Ron was primarily responsible for developing NAN’s lead product, trophon, which is now sold globally with regulatory approvals in major markets including the USA. Ron has led a team identifying unique opportunities for NAN’s new products portfolio, developing the fundamental technologies as well as the business cases supporting them. Dr Weinberger will continue to provide strategic leadership capabilities to the 3DMorphic team including regulatory, intellectual property, and sales. Ron is currently CEO and Managing Director of EMVision, a medical technology company developing new types of medical imaging. Dr Weinberger holds a PhD in medical biochemistry from the University of Newcastle.
Chief Executive Officer: Anthony Harrington GAICD, MBA, B.Sc
A professional executive and non-executive director with over 20 years’ experience in senior roles in the $12 billion Australian medical device sector. Anthony has a total of 8 years accumulated executive directorship expertise and over 3 years’ non-executive directorship experience whilst serving as Vice- Chair on the board of the Medical Technology Association of Australia (MTAA).
Over 20 years’ experience in business management/development with particular emphasis on the successful commercialisation (including D&D to realisation) of high tech medical devices, health tech platforms and multi-site technical services to major public and private hospitals; aged care facilities; pharmacies and primary care clinics in Australia, the UK, Europe and New Zealand. Anthony possesses high order marketing, analytical and investment skills developed via a range of line management roles in the medical device sector in Australia, New Zealand and the UK, coupled with the development and execution of innovative sales and marketing approaches to consistently over-deliver expected sales/ earnings targets. Anthony also possesses direct and extensive merger and acquisition experience and change management process transformation experience.
Chief Technology Officer, co-founder: Dr William C.H. Parr, PhD
Dr Parr holds a PhD in Computational Anatomy (University College London and the Natural History Museum, London), and has held Post-Doctoral Research Fellow positions at the Surgical and Orthopaedic Research Laboratory at the University of New South Wales. Will came to Australia on an Endeavour Postdoctoral Research Fellowship Award from the Australian Government in 2011. Will’s principal areas of expertise are in 3D modelling of anatomy, both with respect to statistical 3D shape analysis and biomechanical analyses (e.g. joint axis determination and bone kinematics, as well as Finite Element Analysis to predict stress and strain distributions), 3D reconstructions of anatomy (hard and soft tissue to create musculoskeletal models) from CT and MRI data, uses of additive manufacturing (3D printing) in medicine (3D printed anatomical models used during the planning of complex surgeries, replication of clinical anatomy to test biomedical devices, 3D printing of patient specific devices). Dr Parr has published peer reviewed scientific journal articles in top ranked journals, and has been an invited speaker at leading international research conferences. He has secured significant competitive government and private competitive merit based funding.
Clinical Advisor: Dr Ralph Mobbs, Neurosurgeon
Dr Ralph Mobbs is a Spinal Neurosurgeon at the Prince of Wales Private and Public Hospitals in Sydney, Australia. He is Director of the NeuroSpineClinic, Chair of the NSURG research group and Editor-in-Chief of the Journal of Spine Surgery, and is clinical Associate Professor in Neurosurgery at the University of New South Wales, Sydney. His clinical expertise is in the areas of spinal tumors, spinal trauma, and minimally invasive spine surgery for degenerative conditions. Over the last 15 years, he has developed new surgical fixation systems and implants, approaches and techniques in common use today. Research interests include: 3D Printing, Bio-materials, Disc Arthroplasty, Minimally Invasive surgical techniques, Wearable technologies, and Stem Cell regenerative therapies. Dr Mobbs is widely recognised as a global leader in the formulation and application of customised, 3d printed, spinal devices. Dr Mobbs is a Fellow of the Royal Australasian College of Surgeons.
Software Developer, Design and Quality Associate: John Ward, Engineer
John is in his fourth year studying a bachelor of mechatronic engineering with a master’s in biomedical engineering at the University of New South Wales. He has a background in orthopaedic research being a lab assistant at the Surgical and Orthopaedic Research Laboratories in the Prince of Wales Hospital. There he was involved in histology, mechanical testing, and various other laboratory activities. He joined 3DMorphic in early June 2020, creating biomodels, processing devices and developing the software used to create the custom implants. Software development has allowed the scalability and mass production of custom spinal fusion devices. John also maintains and advances the Quality Management System.
Software Developer, Design and Quality Associate: Adam Schuman, Engineer
Adam is a fourth year student at the University of New South Wales studying a bachelor of mechanical engineering and computer science. He joined 3DMorphic in September 2020, using his background in computer science to develop the software used to design custom devices. Powerful computer aided design software has greatly reduced the time taken to design spinal fusion devices. Adam also maintains and advances the quality management system.